Roche, Mylan settle Xeloda patent fight; Paladin to lodge Valeant-beating bid for Afexa;

@FiercePharma: CHMP on Multaq: Use after considering alternatives, and only in certain AF patients. For them, benefits > risks $SNY. Item | Follow @FiercePharma

> Roche and Mylan ($MYL) have settled a patent fight over the cancer drug Xeloda with a deal subject to review by the Justice Department and Federal Trade Commission. Details weren't disclosed, but Xeloda's patent is due to expire in 2013. News

> MSMB Capital Management moved to oust all but one of Amag Pharmaceuticals' ($AMAG) directors and block its proposed merger with Allos Therapeutics ($ALTH). Report

> Paladin Labs ($PLB) plans to sweeten its bid for Canada's Afexa Life Sciences ($FXA) enough to top an offer from Valeant Pharmaceuticals ($VRX). Article

> Roche's ($ROG) Avastin won approval from Europe's CHMP for use as a first-line treatment against advanced ovarian cancer in combination with chemo. Roche release

> Gilead Sciences' ($GILD) combination HIV drug Eviplera got a positive recommendation from CHMP, and a decision is expected from the European Commission by year's end. Gilead release

> Novartis' ($NVS) proposed triple-combination blood pressure pill Rasitrio--which comprises the renin inhibitor Rasilez, plus a calcium channel blocker and diuretic--won a positive opinion from Europe's CHMP. Novartis release

Biotech News

 @FierceBiotech: The Latest Sirtuin Controversy. Article Read the excellent article by @Dereklowe. | Follow @FierceBiotech

 @JohnCFierce: In case you missed it: Enzon is chopping its workforce in half. Article | Follow @JohnCFierce

 @RyanMFierce: Anyone really surprised $AZ is going with partner over M&A strategy in China, though? Not aware of many biotechs there ripe for takeovers. | Follow @RyanMFierce

 @MaureenFierce: RT @Loftus: Merck rotavirus vaccine cut hospitalizations, spending, according to CDC. Report | Follow @MaureenFierce

 @FierceMedDev: More exec moves at AngioDynamics: Scott Solano to Depart AngioDynamics. Release | Follow @FierceMedDev

> FDA slams brakes on Immunomedics' cancer trial. Story 

> Getting the most out of your first-in-human studies. News 

> Icahn-backed Enzon Pharma axing half of workers. Item 

And Finally... Anti-wrinkle supplement from Unilever tested in double-blind trial, but how good is the data? Report

Suggested Articles

Talk about making pharma history. Merck's Keytruda has racked up yet another first-of-its-kind approval, this time in a combo with Eisai’s Lenvima.

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.